TBW04810
Cyclo[(2R)-2-hydroxy-3-methylbutanoyl-N-methyl-L-phenylalanyl-(2R)-2-hydroxy-3-methylbutanoyl-N-methyl-L-phenylalanyl-(2R)-2-hydroxy-3-methylbutanoyl-N-methyl-L-phenylalanyl];Beauvericin;beauverin;beauverin bassiaua vuillemin;bovein;Cyclo(-D-a-hydroxyisovaleryl-N-Me-Phe)3;cyclo(D-α-Hydroxyisovaleryl-L-N-methyl-Phe)3;AKOS030622850;NCGC00380798-01;UNII-26S048LS2R;26S048LS2R;CS-W020817;HY-N6739;26048-05-5;(3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-6,12,18-triisopropyl-4,10,16-trimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone;Beauvericin Solution in Acetonitrile, 100ug/mL;NS00018333;1ST7258;CHEBI:3000;CHEMBL249052;DTXSID00891834;(3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-4,10,16-trimethyl-6,12,18-tri(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone;1ST7258-100A;(3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-6,12,18-triisopropyl-4,10,16-trimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexaone;SCHEMBL29355;(3S,6R,9S,12R,15S,18R)-3,9,15-Tribenzyl-4,10,16-trimethyl-6,12,18-tripropan-2-yl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone;J-016236;NSC708472;Cyclo(D-.alpha.-hydroxyisovaleryl-N-methyl-L-phenylalanyl-D~ -.alpha.-hydroxyisovaleryl-N-methyl-L-phenylalanyl-D-.alpha.-hydroxyisovaleryl-N-methyl-L-phenylalanyl);1,13-Trioxa-4,10,16-triazacyclooctadecane, cyclic peptide deriv.;CHEMBL1977672;FT-0602893;NSC-708472;3,9,15-tribenzyl-4,10,16-trimethyl-6,12,18-tri(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone;Beauvericin, VETRANAL(TM), analytical standard;Beauvericin, >=97% (HPLC);Cyclo(D-??-Hydroxyisovaleryl-L-N-methyl-Phe)3;N-Methylcyclo(L-Phe-D-Hmb-N-methyl-L-Phe-D-Hmb-N-methyl-L-Phe-D-Hmb-);NCI60_038416;SCHEMBL6452789
C45H57N3O9
783.95
